Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Enhancing Ribonucleic Acid (RNA) Cancer Vaccines by Combining Circular RNA and Costimulatory Adjuvants
EF 2022-23
Résumé
Cancer vaccines stimulate the immune system to destroy cancer cells that express tumor-specific antigens (TSAs). Lipid nanoparticle (LNP) messenger RNA (mRNA) formulations are emerging cancer vaccine candidates. In these formulations, mRNA encodes for a TSA. LNPs protect and deliver mRNA to antigen presenting cells (APCs), where mRNA translation expresses TSAs and generates immune responses. Naturally, mRNA stimulates the immune system; however, further immune activation with adjuvants is important to generate antibodies and T-cells that kill cancer and generate long-term immunity. Costimulatory molecules are promising adjuvants for cancer vaccines, as they promote antitumour activity through interactions between T-cell receptors and ligands expressed on APCs. However, since mRNA is unstable, immune stimulation with adjuvants causes mRNA degradation and insufficient antigen expression. Circular RNA (circRNA) is a more stable alternative, with more robust antigen expression mechanisms under stress conditions such as immune stimulation. My project aims to evaluate the performance of circRNA and mRNA encoding for a TSA and costimulatory adjuvant. I hypothesize that compared to mRNA, the improved stability and translation of circRNA under stress conditions will enable the integration of TSA and costimulatory adjuvant sequences without sacrificing antigen production, resulting in cancer vaccines with enhanced antitumor activity. To test this hypothesis, in vitro and in vivo tests will assess the RNA-LNPs’ immunogenicity, antigen expression, and antitumor activity. Through this work, I hope to identify a novel circRNA platform for integrating adjuvants in RNA-based vaccines, which may be critical in developing efficacious prophylactic and therapeutic cancer vaccines.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
486081
Name
Tsai Shannon N
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Enhancing Ribonucleic Acid (RNA) Cancer Vaccines by Combining Circular RNA and Costimulatory Adjuvants
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adjuvant; Biomedical Engineering; Cancer Therapy; Circular Rna; Costimulatory Molecules; Immunotherapy; Lipid Nanoparticle; Messenger Rna; Rna Therapeutics; Vaccine
Abstract
Cancer vaccines stimulate the immune system to destroy cancer cells that express tumor-specific antigens (TSAs). Lipid nanoparticle (LNP) messenger RNA (mRNA) formulations are emerging cancer vaccine candidates. In these formulations, mRNA encodes for a TSA. LNPs protect and deliver mRNA to antigen presenting cells (APCs), where mRNA translation expresses TSAs and generates immune responses. Naturally, mRNA stimulates the immune system; however, further immune activation with adjuvants is important to generate antibodies and T-cells that kill cancer and generate long-term immunity. Costimulatory molecules are promising adjuvants for cancer vaccines, as they promote antitumour activity through interactions between T-cell receptors and ligands expressed on APCs. However, since mRNA is unstable, immune stimulation with adjuvants causes mRNA degradation and insufficient antigen expression. Circular RNA (circRNA) is a more stable alternative, with more robust antigen expression mechanisms under stress conditions such as immune stimulation. My project aims to evaluate the performance of circRNA and mRNA encoding for a TSA and costimulatory adjuvant. I hypothesize that compared to mRNA, the improved stability and translation of circRNA under stress conditions will enable the integration of TSA and costimulatory adjuvant sequences without sacrificing antigen production, resulting in cancer vaccines with enhanced antitumor activity. To test this hypothesis, in vitro and in vivo tests will assess the RNA-LNPs’ immunogenicity, antigen expression, and antitumor activity. Through this work, I hope to identify a novel circRNA platform for integrating adjuvants in RNA-based vaccines, which may be critical in developing efficacious prophylactic and therapeutic cancer vaccines.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Tsai, Shannon N
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~